Publications

• Introduction of Allergenic Foods After Treatment with Omalizumab.
  
  05/28/2025 Authors: Dantzer J; Virkud Y; Wang J; Sicherer S; Groetch M; Shreffler W; Pyle D; Kim E; Keet C; Kulis M
• Development of a novel parent-report measure of food allergy impact.
  Acta Paediatr Volume: 114 Page(s): 854 - 862
  05/01/2025 Authors: Proctor KB; Estrem HH; Park J; Wenzell ML; Ravindran M; Sharp WG; Scahill L; Vickery BP
• Towards a common approach for managing food allergy and serious allergic reactions (anaphylaxis) at school. GA2LEN and EFA consensus statement.
  Clin Transl Allergy Volume: 15 Page(s): e70013
  01/01/2025 Authors: Deschildre A; Alvaro-Lozano M; Muraro A; Podesta M; de Silva D; Giovannini M; Barni S; Dribin TE; Sandoval-Ruballos M; Anagnostou A
• EAACI guidelines on the management of IgE-mediated food allergy.
  Allergy Volume: 80 Page(s): 14 - 36
  01/01/2025 Authors: Santos AF; Riggioni C; Agache I; Akdis CA; Akdis M; Alvarez-Perea A; Alvaro-Lozano M; Ballmer-Weber B; Barni S; Beyer K
• Food allergy yardstick: Where does omalizumab fit?
  Ann Allergy Asthma Immunol Volume: 134 Page(s): 110 - 121
  01/01/2025 Authors: Anagnostou A; Greenhawt M; Shaker M; Vickery BP; Wang J
• 10 practical priorities to prevent and manage serious allergic reactions: GA2LEN ANACare and EFA Anaphylaxis Manifesto.
  Clin Transl Allergy Volume: 14 Page(s): e70009
  12/01/2024 Authors: Muraro A; de Silva D; Podesta M; Anagnostou A; Cardona V; Halken S; Smith P; Tanno LK; Turner P; Worm M
• Awareness and Application of United States Food Allergy Prevention Guidelines Among Pediatricians and Other Clinicians.
  J Pediatr Volume: 275 Page(s): 114218
  12/01/2024 Authors: Wang J; Bird JA; Cleary K; Doucette J; du Toit G; Groetch M; Gupta R; Hathaway KH; Klein S; Lack G
• Omalizumab Implementation in Practice: Lessons Learned From the OUtMATCH Study.
  J Allergy Clin Immunol Pract Volume: 12 Page(s): 2947 - 2954
  11/01/2024 Authors: Vickery BP; Bird JA; Chinthrajah RS; Jones SM; Keet CA; Kim EH; Leung DYM; Shreffler WG; Sicherer SH; Sindher S
• Global availability and uptake of psychological services for adults, caregivers and children with food allergy.
  Allergy Volume: 79 Page(s): 2787 - 2797
  10/01/2024 Authors: Knibb RC; Herbert LJ; Jones CJ; Protudjer JLP; Screti C; Roleston C; Brough HA; Warren C; Lombard L; Santos AF
• The Intersection of Autism Spectrum Disorder, Food Allergy, and Avoidant/Restrictive Food Intake Disorder: A Clinical Case Study.
  J Pediatr Volume: 269 Page(s): 113965
  06/01/2024 Authors: Proctor KB; Volkert VM; Klin A; Vickery BP; Sharp WG
• Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent.
  J Allergy Clin Immunol Volume: 153 Page(s): 1621 - 1633
  06/01/2024 Authors: Mack DP; Dribin TE; Turner PJ; Wasserman RL; Hanna MA; Shaker M; Tang MLK; Rodrguez Del Ro P; Sobolewski B; Abrams EM
• Comment on Hill and colleagues.
  Pediatr Allergy Immunol Volume: 35 Page(s): e14162
  05/01/2024 Authors: Proctor KB; Sharp WG; Vickery BP
• Altered Symptom Perception in Children With Asthma Is Associated With Poor Childhood Opportunity and Adverse Outcomes.
  J Allergy Clin Immunol Pract Volume: 12 Page(s): 983 - 990
  04/01/2024 Authors: Fitzpatrick AM; Kavalieratos D; Vickery BP; Lee T; Mason C; Grunwell JR
• The Future of Food Allergy Management: Advancements in Therapies.
  Curr Allergy Asthma Rep Volume: 24 Page(s): 161 - 171
  04/01/2024 Authors: Ezhuthachan ID; Beaudoin M; Nowak-Wegrzyn A; Vickery BP
• Omalizumab for the Treatment of Multiple Food Allergies.
  N Engl J Med Volume: 390 Page(s): 889 - 899
  03/07/2024 Authors: Wood RA; Togias A; Sicherer SH; Shreffler WG; Kim EH; Jones SM; Leung DYM; Vickery BP; Bird JA; Spergel JM
• Identifying Children at Risk of Growth and Nutrient Deficiencies in the Food Allergy Clinic.
  J Allergy Clin Immunol Pract Volume: 12 Page(s): 579 - 589
  03/01/2024 Authors: Venter C; Meyer R; Bauer M; Bird JA; Fleischer DM; Nowak-Wegrzyn A; Anagnostou A; Vickery BP; Wang J; Groetch M
• Exploratory immunogenicity outcomes of peanut oral immunotherapy: Findings from the PALISADE trial.
  Clin Transl Allergy Volume: 14 Page(s): e12326
  01/01/2024 Authors: Nilsson C; Vereda A; Borres MP; Andersson M; Sdergren E; Rudengren M; Smith A; Simon RJ; Ryan R; Fernndez-Rivas M
• EAACI guidelines on the diagnosis of IgE-mediated food allergy.
  Allergy Volume: 78 Page(s): 3057 - 3076
  12/01/2023 Authors: Santos AF; Riggioni C; Agache I; Akdis CA; Akdis M; Alvarez-Perea A; Alvaro-Lozano M; Ballmer-Weber B; Barni S; Beyer K
• Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age.
  NEJM Evid Volume: 2 Page(s): EVIDoa2300145
  11/01/2023 Authors: Du Toit G; Brown KR; Vereda A; Irani A-M; Tilles S; Ratnayake A; Jones SM; Vickery BP
• Food Oral Immunotherapy: A Survey Among US Practicing Allergists Conducted as a AAAAI Leadership Institute Project and Work Group Report.
  J Allergy Clin Immunol Pract Volume: 11 Page(s): 2330 - 2334
  08/01/2023 Authors: Anagnostou A; Vickery B
• Social determinants of health influence preschool and caregiver experiences during symptoms and exacerbations of wheezing.
  Ann Allergy Asthma Immunol Volume: 131 Page(s): 75 - 81.e3
  07/01/2023 Authors: Fitzpatrick AM; Lee T; Vickery BP; Corace EA; Mason C; Norwood J; Caldwell C; Grunwell JR
• Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.
  N Engl J Med Volume: 388 Page(s): 1755 - 1766
  05/11/2023 Authors: Greenhawt M; Sindher SB; Wang J; O'Sullivan M; du Toit G; Kim EH; Albright D; Anvari S; Arends N; Arkwright PD
• Randomized controlled trial of slow peanut oral immunotherapy in young children: SmaChO study protocol.
  Clin Exp Allergy Volume: 53 Page(s): 594 - 597
  05/01/2023 Authors: Uhl C; Sverremark-Ekstrm E; Borres M; Ebisawa M; Meln E; Mkel MJ; Konradsen JR; Vickery BP; Asarnoj A; Nilsson C
• Food Allergen Immunotherapy in Preschool Children: Do We Have the Evidence?
  J Allergy Clin Immunol Pract Volume: 11 Page(s): 1028 - 1035
  04/01/2023 Authors: Loke P; Vickery BP; Jones SM; Peters RL; Roberts G; Koplin JJ
• Food Allergy Management Practices Utilizing Individual Patient Thresholds: A Work Group Report of the AAAAI Adverse Reactions to Foods Committee.
  J Allergy Clin Immunol Pract Volume: 11 Page(s): 1083 - 1086.e1
  04/01/2023 Authors: Oriel RC; Shah A; Anagnostou A; Greenhawt M; Khan F; Leeds S; Ravindran M; Stoffels G; Vickery BP; Virkud YV
• WAO consensus on DEfinition of Food Allergy SEverity (DEFASE).
  World Allergy Organ J Volume: 16 Page(s): 100753
  03/01/2023 Authors: Arasi S; Nurmatov U; Dunn-Galvin A; Roberts G; Turner PJ; Shinder SB; Gupta R; Eigenmann P; Nowak-Wegrzyn A; Ansotegui IJ
• Retail Food Equivalents for Post-Oral Immunotherapy Dosing in the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy in Food-Allergic Children and Adults(OUtMATCH) Clinical Trial.
  J Allergy Clin Immunol Pract Volume: 11 Page(s): 572 - 580.e2
  02/01/2023 Authors: Groetch M; Mudd K; Woch M; Schaible A; Gray BE; Babineau DC; Bird JA; Jones S; Kim EH; Lanser BJ
• Current and future treatments for peanut allergy.
  Clin Exp Allergy Volume: 53 Page(s): 10 - 24
  01/01/2023 Authors: Lee T; Edwards-Salmon S; Vickery BP
• Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.
  Ann Allergy Asthma Immunol Volume: 129 Page(s): 758 - 768.e4
  12/01/2022 Authors: Ciaccio C; Goldsobel AB; Anagnostou A; Beyer K; Casale TB; Deschildre A; Fernndez-Rivas M; Hourihane JO; Krawiec M; Lieberman J
• GENETICALLY CONFIRMED TYPE I LEUKOCYTE ADHESION DEFICIENCY IN A TWO-YEAR-OLD MALE
  Volume: 129 Page(s): S137 - S137
  11/01/2022 Authors: Edwards-Salmon S; Chandrakasan S; Vickery B
• Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH).
  J Allergy Clin Immunol Glob Volume: 1 Page(s): 225 - 232
  11/01/2022 Authors: Wood RA; Chinthrajah RS; Rudman Spergel AK; Babineau DC; Sicherer SH; Kim EH; Shreffler WG; Jones SM; Leung DYM; Vickery BP
• Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy.
  J Allergy Clin Immunol Volume: 150 Page(s): 1144 - 1153
  11/01/2022 Authors: Kulis MD; Smeekens JM; Burk C; Yue X; Guo R; Orgel KA; Ye P; Herlihy L; Hamilton D; Li Q
• Production and Standardization of Palforzia for Use as oral Immunotherapy
  Volume: 45 Page(s): 594 - 594
  08/01/2022 Authors: Leonard SA; Gladbach A; Ogawa Y; Jedrzejewski PT; Laverdiere A; Maleki SJ; Chapman MD; Tilles SA; Du Toit G; Mustafa SS
• Continued safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled analysis from controlled and open-label phase 3 trials
  Volume: 52 Page(s): 1042 - 1042
  08/01/2022 Authors: Baker J; Bird JA; Burks AW; Hourihane JO; Beyer K; Vickery BP; Jones SM; du Toit G; Tilles SA; Smith A
• Mechanisms of immune response and relationship to clinical reactivity during oral immunotherapy with peanut (Arachis hypogaea) allergen powder-dnfp: Findings from the phase 3 PALISADE trial
  Volume: 52 Page(s): 1031 - 1032
  08/01/2022 Authors: Bajzik V; DeBerg HA; Irani A-M; Ryan R; du Toit G; Vickery BP; Wambre E
• Caregivers' experiences of accessing mental health services for food allergy related distress: Data from the GAPS study
  Volume: 52 Page(s): 1029 - 1030
  08/01/2022 Authors: Knibb R; Screti C; Warren C; Brough H; Herbert L; Jones C; Lombard L; Protudjer J; Santos A; Gupta R
• Manufacturing and standardization of peanut (Arachis hypogaea) allergen powder-dnfp for use as an oral immunotherapy: Peanut flour source material lot testing
  Volume: 52 Page(s): 1040 - 1040
  08/01/2022 Authors: Leonard SA; Ogawa Y; Jedrzejewski P; Laverdiere A; Maleki SJ; Chapman MD; Tilles SA; du Toit G; Mustafa SS; Yassine M
• Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses.
  Allergy Volume: 77 Page(s): 2534 - 2548
  08/01/2022 Authors: Bajzik V; DeBerg HA; Garabatos N; Rust BJ; Obrien KK; Nguyen Q-A; O'Rourke C; Smith A; Walker AH; Quinn C
• A practical focus on peanut oral immunotherapy.
  J Food Allergy Volume: 4 Page(s): 112 - 119
  07/01/2022 Authors: Lee T; Horton C; Leef C; Vickery BP
• REALISE-ing the Net Health Benefit of EPIT for Peanut Allergy.
  J Allergy Clin Immunol Pract Volume: 10 Page(s): 1874 - 1875
  07/01/2022 Authors: Vickery BP
• Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials.
  J Allergy Clin Immunol Volume: 149 Page(s): 2043 - 2052.e9
  06/01/2022 Authors: Brown KR; Baker J; Vereda A; Beyer K; Burks AW; du Toit G; O'B Hourihane J; Jones SM; Norval D; Dana A
• A systematic review of parent report measures assessing the psychosocial impact of food allergy on patients and families.
  Allergy Volume: 77 Page(s): 1347 - 1359
  05/01/2022 Authors: Proctor KB; Tison K; H Estrem H; Park J; Scahill L; Vickery BP; Sharp WG
• Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
  Allergy Volume: 77 Page(s): 991 - 1003
  03/01/2022 Authors: Fernandez-Rivas M; Vereda A; Vickery BP; Sharma V; Nilsson C; Muraro A; Hourihane JO; DunnGalvin A; du Toit G; Blumchen K
• Content Validation of the Psychosocial Evaluation of Allergy on Caregivers and Households (PEACH) Tool
  Volume: 149 Page(s): AB119 - AB119
  02/01/2022 Authors: Ravindran M; Park J; Estrem H; Sharp W; Vickery B
• Global Availability and Uptake of Psychological Services for Caregivers of Children with Food Allergy
  Volume: 149 Page(s): AB120 - AB120
  02/01/2022 Authors: Herbert L; Knibb R; Brough H; Jones C; Lombard L; Protudjer J; Santos A; Vickery B; Gupta R; Screti C
• Peanut Sensitization is Associated with Greater Respiratory Morbidity in Preschool Children with Comorbid Asthma
  Volume: 149 Page(s): AB135 - AB135
  02/01/2022 Authors: Offerle T; Vickery B; Lee G; Fitzpatrick A
• Baseline Clinical and Immunologic Characteristics of Children Screened in the Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON) Trial
  Volume: 149 Page(s): AB31 - AB31
  02/01/2022 Authors: Vickery B; du Toit G; Ratnayake A; Blumchen K; Sharma V; Chapman J; Deschildre A; Sher L; Norval D; Adelman D
• Protocol for a systematic review of the diagnostic test accuracy of tests for IgE-mediated food allergy.
  Pediatr Allergy Immunol Volume: 33 Page(s): e13684
  01/01/2022 Authors: Genuneit J; Jayasinghe S; Riggioni C; Peters RL; Chu DK; Munblit D; Boyle RJ; Du Toit G; Skypala I; Santos AF
• Exploring barriers to commercial peanut oral immunotherapy treatment during COVID-19.
  J Allergy Clin Immunol Pract Volume: 10 Page(s): 309 - 311.e1
  01/01/2022 Authors: Leef C; Horton C; Lee T; Lee G; Tison K; Vickery BP
• Food Insecurity in the Food Allergic Population: AWork Group Report of the AAAAI Adverse Reactions to Foods Committee.
  J Allergy Clin Immunol Pract Volume: 10 Page(s): 81 - 90
  01/01/2022 Authors: Shroba J; Das R; Bilaver L; Vincent E; Brown E; Polk B; Ramos A; Russell AF; Bird JA; Ciaccio CE
• Avoidant-restrictive food intake disorder (ARFID): A treatable complication of foodallergy.
  J Allergy Clin Immunol Pract Volume: 10 Page(s): 326 - 328.e2
  01/01/2022 Authors: Patrawala MM; Vickery BP; Proctor KB; Scahill L; Stubbs KH; Sharp WG
• Manufacturing processes of peanut (Arachis hypogaea) allergen powder-dnfp.
  Front Allergy Volume: 3 Page(s): 1004056
  01/01/2022 Authors: Leonard SA; Ogawa Y; Jedrzejewski PT; Maleki SJ; Chapman MD; Tilles SA; Du Toit G; Mustafa SS; Vickery BP
• Treatment satisfaction with continued oral immunotherapy for peanut allergy: results after 1, 1.5, and 2 years of daily therapy
  Volume: 76 Page(s): 7 - 9
  11/01/2021 Authors: Bluemchen K; Hass S; Beyer K; Du Toit G; O'B Hourihane J; Shreffler WG; Vickery BP; Vereda A; Smith A; Brown K
• Oral Immunotherapy-Related Awareness, Attitudes, and Experiences Among a Nationally Representative Sample of Food Allergy Patients/Caregivers.
  J Allergy Clin Immunol Pract Volume: 9 Page(s): 4087 - 4094.e3
  11/01/2021 Authors: Warren CM; Roach A; Das R; Casale TB; Vickery BP; Wasserman RL; Gupta RS
• Management of Eosinophilic Esophagitis During Oral Immunotherapy.
  J Allergy Clin Immunol Pract Volume: 9 Page(s): 3282 - 3287
  09/01/2021 Authors: Chu DK; Spergel JM; Vickery BP
• The use of biologics in food allergy.
  Clin Exp Allergy Volume: 51 Page(s): 1006 - 1018
  08/01/2021 Authors: Fiocchi A; Vickery BP; Wood RA
• Performance of Eosinophil Cationic Protein as a Biomarker in Asthmatic Children.
  J Allergy Clin Immunol Pract Volume: 9 Page(s): 2761 - 2769.e2
  07/01/2021 Authors: Shah SN; Grunwell JR; Mohammad AF; Stephenson ST; Lee GB; Vickery BP; Fitzpatrick AM
• Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study.
  J Allergy Clin Immunol Pract Volume: 9 Page(s): 1879 - 1889.e13
  05/01/2021 Authors: Vickery BP; Vereda A; Nilsson C; du Toit G; Shreffler WG; Burks AW; Jones SM; Fernndez-Rivas M; Blmchen K; O'B Hourihane J
• Consensus on DEfinition of Food Allergy SEverity (DEFASE) an integrated mixed methods systematic review.
  World Allergy Organ J Volume: 14 Page(s): 100503
  03/01/2021 Authors: Arasi S; Nurmatov U; Dunn-Galvin A; Daher S; Roberts G; Turner PJ; Shinder SB; Gupta R; Eigenmann P; Nowak-Wegrzyn A
• Safety of Peanut (Arachis Hypogaea) Allergen Powder-dnfp in Children and Teenagers With Peanut Allergy: Pooled Analysis From Controlled and Open-Label Phase 3 Trials
  Volume: 147 Page(s): AB106 - AB106
  02/01/2021 Authors: Casale T; Wesley Burks A; Baker J; Hourihane JO; Beyer K; Vickery B; Jones S; Du Toit G; Bird JA; Smith A
• Patients' Perspectives and Needs on Novel Food Allergy Treatments in the United States.
  Curr Treat Options Allergy Volume: 8 Page(s): 9 - 20
  01/01/2021 Authors: Herbert L; Marchisotto MJ; Vickery B
• Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation.
  Contemp Clin Trials Volume: 100 Page(s): 106228
  01/01/2021 Authors: Phipatanakul W; Mauger DT; Guilbert TW; Bacharier LB; Durrani S; Jackson DJ; Martinez FD; Fitzpatrick AM; Cunningham A; Kunselman S
• Five-year follow-up of early intervention peanut oral immunotherapy.
  J Allergy Clin Immunol Pract Volume: 9 Page(s): 514 - 517
  01/01/2021 Authors: Herlihy L; Kim EH; Burks AW; Barber H; Cook Q; Yang L; Hamilton D; Vickery BP
• Consensus on DEfinition of Food Allergy SEverity (DEFASE): Protocol for a systematic review.
  World Allergy Organ J Volume: 13 Page(s): 100493
  12/01/2020 Authors: Arasi S; Nurmatov U; Turner PJ; Ansotegui IJ; Daher S; Dunn-Galvin A; Ebisawa M; Eigenmann P; Fernandez-Rivas M; Gupta R
• Shared decision-making in food allergy management.
  J Food Allergy Volume: 2 Page(s): 124 - 127
  09/01/2020 Authors: Patrawala M; Lee G; Vickery B
• PALISADE follow-on study (ARC004): Longer-term outcomes with AR101 oral immunotherapy for peanut allergy
  Volume: 75 Page(s): 258 - 259
  08/01/2020 Authors: Fernandez-Rivas M; Hourihane JO; Blumchen K; Jones SM; Shreffler WG; Du Toit G; Muraro A; Beyer K; Sprikkelman A; Smith A
• Consensus report from the Food Allergy Research & Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit.
  J Allergy Clin Immunol Volume: 146 Page(s): 244 - 249
  08/01/2020 Authors: Pepper AN; Assa'ad A; Blaiss M; Brown E; Chinthrajah S; Ciaccio C; Fasano MB; Gupta R; Hong N; Lang D
• THE ESTIMATED RISK REDUCTION OF ANAPHYLACTIC REACTIONS ASSOCIATED WITH AR101 ORAL IMMUNOTHERAPY FOLLOWING ACCIDENTAL PEANUT EXPOSURE: AN ANALYSIS BASED ON CLINICAL TRIAL DATA
  Volume: 23 Page(s): S371 - S371
  05/01/2020 Authors: Tilles S; Yu S; Smith A; Wu E; Zhou J; Chai X; Wei LJ; Robison DR; Hass SL; Donelson S
• Peanut Oral Immunotherapy: a Current Perspective.
  Curr Allergy Asthma Rep Volume: 20 Page(s): 14
  04/20/2020 Authors: Patrawala M; Shih J; Lee G; Vickery B
• A Novel Allergen-Specific Immune Signature-Directed Approach to Dietary Elimination in Eosinophilic Esophagitis.
  Clin Transl Gastroenterol Volume: 10 Page(s): e00099
  12/01/2019 Authors: Dellon ES; Guo R; McGee SJ; Hamilton DK; Nicolai E; Covington J; Moist SE; Arrington A; Wright BL; Burks AW
• IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy.
  Pediatr Allergy Immunol Volume: 30 Page(s): 817 - 823
  12/01/2019 Authors: Dreskin SC; Germinaro M; Reinhold D; Chen X; Vickery BP; Kulis M; Burks AW; Negi SS; Braun W; Chambliss JM
• Baseline demographics of > 1100 peanut-allergic subjects aged 4-17 years randomised in three double-blind placebo-controlled phase 3 AR101 trials: Palisade, RAMSES and ARTEMIS
  Volume: 74 Page(s): 301 - 301
  08/01/2019 Authors: Beyer K; Abbas AS; Brown K; Norval D; Burks AW; Casale TB; Du Toit G; Hourihane JO; Jones SM; Shreffler WG
• Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy-An NIAID/AHRQ Workshop.
  J Allergy Clin Immunol Volume: 143 Page(s): 1711 - 1726
  05/01/2019 Authors: Wheatley LM; Wood R; Nadeau K; Liu A; Zoratti E; Bacharier L; Brittain E; Calderon M; Casale T; Chipps B
• Genetic variants at the 16p13 locus confer risk for eosinophilic esophagitis.
  Genes Immun Volume: 20 Page(s): 281 - 292
  04/01/2019 Authors: Kottyan LC; Maddox A; Braxton JR; Stucke EM; Mukkada V; Putnam PE; Abonia JP; Chehade M; Wood RA; Pesek RD
• Oral Immunotherapy for Peanut Allergy.
  N Engl J Med Volume: 380 Page(s): 691 - 692
  02/14/2019 Authors: Vickery BP; Hourihane JO; Adelman DC
• Current and Future Treatment of Peanut Allergy.
  J Allergy Clin Immunol Pract Volume: 7 Page(s): 357 - 365
  02/01/2019 Authors: Vickery BP; Ebisawa M; Shreffler WG; Wood RA
• Prevention of food allergy: Beyond peanut.
  J Allergy Clin Immunol Volume: 143 Page(s): 545 - 547
  02/01/2019 Authors: Bird JA; Parrish C; Patel K; Shih JA; Vickery BP
• Evaluating primary end points in peanut immunotherapy clinical trials.
  J Allergy Clin Immunol Volume: 143 Page(s): 494 - 506
  02/01/2019 Authors: Rodrguez Del Ro P; Escudero C; Snchez-Garca S; Ibez MD; Vickery BP
• High- and low-dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children.
  Clin Exp Allergy Volume: 49 Page(s): 180 - 189
  02/01/2019 Authors: Kulis M; Yue X; Guo R; Zhang H; Orgel K; Ye P; Li Q; Liu Y; Kim E; Burks AW
• Five Year Follow-Up Of Early Intervention Peanut OIT Showed Characteristics of Sustained and Prolonged Clinical Benefit
  Volume: 143 Page(s): AB264 - AB264
  02/01/2019 Authors: Herlihy L; Kim E; Hamad A; Cook Q; Hamilton DK; Barber H; Burks AW; Vickery BP
• Estimating the Probability of Tolerating Each Challenge Dose of Peanut Protein at Exit Double-Blind, Placebo-Controlled Food Challenge: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE) of AR101
  Volume: 143 Page(s): AB262 - AB262
  02/01/2019 Authors: Carr W; Vickery BP; Zawadzki R; Griffin NM; Adelman DC; Kim E
• Can Omalizumab Monotherapy Benefit Real-World Food Allergy Patients? Lessons From an Observational Study.
  J Allergy Clin Immunol Pract Volume: 7 Page(s): 1910 - 1911
  01/01/2019 Authors: Vickery BP
• AR101 Oral Immunotherapy for Peanut Allergy.
  N Engl J Med Volume: 379 Page(s): 1991 - 2001
  11/22/2018 Authors: PALISADE Group of Clinical Investigators; Vickery BP; Vereda A; Casale TB; Beyer K; du Toit G; Hourihane JO; Jones SM; Shreffler WG; Marcantonio A
• Efficacy and safety of AR101: results of the phase 3 peanut allergy oral immunotherapy study for desensitization (PALISADE)
  Volume: 48 Page(s): 1529 - 1529
  11/01/2018 Authors: Hourihane JO; Vereda A; Jones S; Burks AW; Zawadzki R; Casale T; Shreffler W; Matthews J; McIntosh S; Vickery B
• Development of a patient-centric food allergy research program: A model for action.
  Allergy Volume: 73 Page(s): 1551 - 1553
  07/01/2018 Authors: Bute JJ; Broome SB; Marcus JN; Mikulcik S; Vickery B
• Specific allergen profiles of peanut foods and diagnostic or therapeutic allergenic products.
  J Allergy Clin Immunol Volume: 141 Page(s): 626 - 631.e7
  02/01/2018 Authors: Filep S; Block DS; Smith BRE; King EM; Commins S; Kulis M; Vickery BP; Chapman MD
• Exploration of Non-Daily Maintenance Dosing Regimens in Peanut Oral Immunotherapy
  Volume: 141 Page(s): AB245 - AB245
  02/01/2018 Authors: Prescott K; Krantz K; Beyer K; Burks AW; Casale TB; Hourihane JO; Jones SM; Vereda A; Vickery BP; Adelman DC
• Immune mechanisms of oral immunotherapy.
  J Allergy Clin Immunol Volume: 141 Page(s): 491 - 498
  02/01/2018 Authors: Kulis MD; Patil SU; Wambre E; Vickery BP
• Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food AllergyResearch.
  J Allergy Clin Immunol Pract Volume: 6 Page(s): 1534 - 1544.e5
  01/01/2018 Authors: Chehade M; Jones SM; Pesek RD; Burks AW; Vickery BP; Wood RA; Leung DYM; Furuta GT; Fleischer DM; Henning AK
• Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.
  J Allergy Clin Immunol Pract Volume: 6 Page(s): 476 - 485.e3
  01/01/2018 Authors: Bird JA; Spergel JM; Jones SM; Rachid R; Assa'ad AH; Wang J; Leonard SA; Laubach SS; Kim EH; Vickery BP
• A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders.
  Sci Transl Med Volume: 9
  08/02/2017 Authors: Wambre E; Bajzik V; DeLong JH; O'Brien K; Nguyen Q-A; Speake C; Gersuk VH; DeBerg HA; Whalen E; Ni C
• Clinical and immunologic characteristics of European patients screened for palisade (peanut allergy oral immunotherapy study of AR101 for desensitization in children and adults)
  Volume: 72 Page(s): 277 - 277
  08/01/2017 Authors: Vereda A; Ibanez M; Beyer K; Burks WA; Casale TB; Hourihane JO; Jones SM; Radwan A; Vickery BP; Adelman DC
• Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults.
  J Allergy Clin Immunol Volume: 139 Page(s): 1242 - 1252.e9
  04/01/2017 Authors: Jones SM; Sicherer SH; Burks AW; Leung DYM; Lindblad RW; Dawson P; Henning AK; Berin MC; Chiang D; Vickery BP
• Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy.
  J Allergy Clin Immunol Volume: 139 Page(s): 882 - 888.e5
  03/01/2017 Authors: Virkud YV; Burks AW; Steele PH; Edwards LJ; Berglund JP; Jones SM; Scurlock AM; Perry TT; Pesek RD; Vickery BP
• Dual assessment of peanut-specific effector and regulatory T cells in patients undergoing oral immunotherapy
  Volume: 139 Page(s): AB257 - AB257
  02/01/2017 Authors: Rust BJ; Bajzik V; Vickery BP; Wambre ER
• Six month course of peanut OIT leads to suppression of basophil activation which begins to wane within four weeks after OIT is stopped
  Volume: 139 Page(s): AB135 - AB135
  02/01/2017 Authors: Kulis MD; Burk CM; Yue X; Zhang H; Guo R; Orgel K; Ye P; Vickery BP; Kim E; Burks AW
• Low and High Dose Peanut Oral Immunotherapy (OIT) Similarly Suppress Th2 Cytokine and Basophil Activation Responses
  Volume: 139 Page(s): AB176 - AB176
  02/01/2017 Authors: Yue X; Kulis MD; Zhang H; Guo R; Orgel K; Kim E; Burks AW; Vickery BP
• Outcome of 583 Entry Double-Blind Placebo-Controlled Peanut Challenges during Screening for the Palisade Phase 3 Oral Immunotherapy Trial
  Volume: 139 Page(s): AB381 - AB381
  02/01/2017 Authors: Vickery BP; Beyer K; Burks AW; Casale TB; Hourihane JO; Jones SM; Radwan A; Vereda A; Adelman DC
• Conducting an Oral Food Challenge to Peanut in an Infant.
  J Allergy Clin Immunol Pract Volume: 5 Page(s): 301 - 311.e1
  01/01/2017 Authors: Bird JA; Groetch M; Allen KJ; Bock SA; Leonard S; Nowak-Wegrzyn AH; Sicherer S; Clark A; Fleischer DM; Venter C
• Eosinophilic esophagitis during peanut oral immunotherapy with omalizumab.
  J Allergy Clin Immunol Pract Volume: 5 Page(s): 498 - 501
  01/01/2017 Authors: Burk CM; Dellon ES; Steele PH; Virkud YV; Kulis M; Burks AW; Vickery BP
• Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.
  J Allergy Clin Immunol Volume: 139 Page(s): 173 - 181.e8
  01/01/2017 Authors: Vickery BP; Berglund JP; Burk CM; Fine JP; Kim EH; Kim JI; Keet CA; Kulis M; Orgel KG; Guo R
• Exploiting CD22 on antigen-specific Bcells to prevent allergy to the major peanut allergen Ara h 2.
  J Allergy Clin Immunol Volume: 139 Page(s): 366 - 369.e2
  01/01/2017 Authors: Orgel KA; Duan S; Wright BL; Maleki SJ; Wolf JC; Vickery BP; Burks AW; Paulson JC; Kulis MD; Macauley MS
• Low dose immunotherapy in very young children to treat peanut allergy.
  Expert Rev Clin Immunol Volume: 12 Page(s): 1251 - 1253
  12/01/2016 Authors: Vickery BP
• Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness.
  Allergy Volume: 71 Page(s): 1552 - 1560
  11/01/2016 Authors: Wright BL; Kulis M; Orgel KA; Burks AW; Dawson P; Henning AK; Jones SM; Wood RA; Sicherer SH; Lindblad RW
• Food-specific IgG4 is associated with eosinophilic esophagitis.
  J Allergy Clin Immunol Volume: 138 Page(s): 1190 - 1192.e3
  10/01/2016 Authors: Wright BL; Kulis M; Guo R; Orgel KA; Wolf WA; Burks AW; Vickery BP; Dellon ES
• The safety and tolerability of AR101, an oral immunotherapy (OIT) pharmaceutical formulation for peanut allergy, after more than 1 year of treatment: results from an ongoing phase 2b clinical trial (ARC002), including low-dose (300 mg/day) and high-dose (2000 mg/day) maintenance regimens
  Volume: 71 Page(s): 105 - 105
  08/01/2016 Authors: Rachid RA; Bird JA; Spergel JM; Jones SM; Assa'ad AH; Vickery B; Wang J; Leonard SA; Laubach SS; Kim EH
• Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy.
  J Allergy Clin Immunol Volume: 137 Page(s): 1117 - 1127.e10
  04/01/2016 Authors: Jones SM; Burks AW; Keet C; Vickery BP; Scurlock AM; Wood RA; Liu AH; Sicherer SH; Henning AK; Lindblad RW
• Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy.
  Clin Exp Allergy Volume: 46 Page(s): 347 - 353
  02/01/2016 Authors: Burk CM; Kulis M; Leung N; Kim EH; Burks AW; Vickery BP
• Food-Specific IgG4 Is Associated with Eosinophilic Esophagitis
  Volume: 137 Page(s): AB232 - AB232
  02/01/2016 Authors: Wright BL; Kulis MD; Guo R; Orgel K; Wolf WA; Burks AW; Vickery BP; Dellon ES
• Sublingual Immunotherapy (SLIT) Regulates the Expression of Transcription Factors and Interleukins in Peanut Allergic Children
  Volume: 137 Page(s): AB194 - AB194
  02/01/2016 Authors: Ye P; Kulis MD; Guo R; Kim EH; Vickery BP; Burks AW
• 11q13 Is an Allergic Risk-Locus That Increases Eoe Risk and Increases LRRC32 Expression
  Volume: 137 Page(s): AB279 - AB279
  02/01/2016 Authors: Kottyan LC; D'Mello RJ; Miller D; Maddox A; Stucke E; Rochman M; Patel Z; Rothenberg JA; Davis BP; Chehade M
• NMR-Based Metabolomics Analysis Reproducibly Identifies Unique Subject-Specific Profiles That Change during Peanut Oral Immunotherapy
  Volume: 137 Page(s): AB132 - AB132
  02/01/2016 Authors: Vickery BP; Kulis MD; Stewart D; Pathmasiri W; Hamilton DK; McRitchie S; Burgess JP; Sumner S; Burks AW
• Siglec-Engaging Tolerance-Inducing Antigenic Liposomes (STALs) in the Prevention of Peanut Allergy
  Volume: 137 Page(s): AB89 - AB89
  02/01/2016 Authors: Orgel K; Duan S; Paulson JC; Burks AW; Vickery BP; Kulis MD; Macauley MS
• Determinants of Peanut Allergy in an Observational Study (CoFAR2) of Food Allergy
  Volume: 137 Page(s): AB152 - AB152
  02/01/2016 Authors: Sicherer SH; Wood RA; Perry TT; Vickery BP; Jones SM; Leung DY; Blackwell B; Dawson P; Burks AW; Lindblad RW
• The Efficacy of AR101, a Peanut-Derived Pharmaceutical for Oral Immunotherapy (OIT), Is Maintained and Tolerability Is Increased with Low-Dose Maintenance Therapy
  Volume: 137 Page(s): AB408 - AB408
  02/01/2016 Authors: Bird JA; Spergel JM; Jones SM; Rachid RA; Assa'ad AH; Wang J; Leonard SA; Laubach SS; Kim EH; Davis BP
• Oral Immunotherapy for Food Allergy.
  Immunol Allergy Clin North Am Volume: 36 Page(s): 55 - 69
  02/01/2016 Authors: Burbank AJ; Sood P; Vickery BP; Wood RA
• Impact of Allergic Reactions on Food-Specific IgE Concentrations and Skin Test Results.
  J Allergy Clin Immunol Pract Volume: 4 Page(s): 239 - 45.e4
  01/01/2016 Authors: Sicherer SH; Wood RA; Vickery BP; Perry TT; Jones SM; Leung DYM; Blackwell B; Dawson P; Burks AW; Lindblad R
• Clinical Management of Food Allergy.
  Pediatr Clin North Am Volume: 62 Page(s): 1409 - 1424
  12/01/2015 Authors: Wright BL; Walkner M; Vickery BP; Gupta RS
• Current Options for the Treatment of Food Allergy.
  Pediatr Clin North Am Volume: 62 Page(s): 1531 - 1549
  12/01/2015 Authors: Lanser BJ; Wright BL; Orgel KA; Vickery BP; Fleischer DM
• A novel characterized peanut allergen formulation (AR101) for oral immunotherapy (OIT) induces desensitization in peanut-allergic subjects: a Phase 2 clinical safety and efficacy study
  Volume: 70 Page(s): 110 - 110
  09/01/2015 Authors: Bird JA; Spergel JM; Jones SM; Rachid R; Assa'ad AH; Wang J; Leonard SA; Laubach SS; Kim EH; Vickery BP
• Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.
  J Allergy Clin Immunol Volume: 135 Page(s): 1240-8.e1-3
  05/01/2015 Authors: Burks AW; Wood RA; Jones SM; Sicherer SH; Fleischer DM; Scurlock AM; Vickery BP; Liu AH; Henning AK; Lindblad R
• High Rate of Sustained Unresponsiveness with Early-Intervention Peanut Oral Immunotherapy
  Volume: 135 Page(s): AB155 - AB155
  02/01/2015 Authors: Vickery BP; Beavers A; Berglund J; French JP; Hamilton DK; Herlihy L; Kim EH; Kulis MD; Szczepanski N; Steele PH
• Impact of Clinical Reactions on IgE Concentrations to Egg, Milk and Peanut in the Observational Cohort of the Consortium for Food Allergy Research (COFAR)
  Volume: 135 Page(s): AB23 - AB23
  02/01/2015 Authors: Sicherer SH; Wood RA; Jones SM; Perry TT; Vickery BP; Burks AW; Liu AH; Leung DYM; Lindblad RW; Dawson P
• Stratification of Health Risk Posed By Allergic Responses at Peanut Threshold Doses: A Pilot Study
  Volume: 135 Page(s): AB256 - AB256
  02/01/2015 Authors: Luccioli S; Zhu J; Fleischer DM; Hiemstra W; Kim EH; Leung SB; Lindblad RW; Mudd KE; Reames R; Steele PH
• Egg-Specific IgA and IgA2 Are Associated with Sustained Unresponsiveness to Egg Following Oral Immunotherapy
  Volume: 135 Page(s): AB38 - AB38
  02/01/2015 Authors: Wright BL; Kulis MD; Orgel K; Burks AW; Dawson P; Jones SM; Wood RA; Sicherer SH; Lindblad RW; Stablein D
• Phenotypic Analysis of Peanut-Responsive T Cells at Baseline in Subjects Enrolled in CoFAR6, a Randomized Placebo-Controlled Epicutaneous Immunotherapy (EPIT) Trial for the Treatment of Peanut Allergy
  Volume: 135 Page(s): AB226 - AB226
  02/01/2015 Authors: Chiang D; Burks AW; Davidson W; Dawson P; Grishin A; Henning A; Jones SM; Leung DYM; Lindblad RW; Liu AH
• Safety of Food Allergy Clinical Trials: The Consortium for Food Allergy Research's 10 Years of Experience
  Volume: 135 Page(s): AB234 - AB234
  02/01/2015 Authors: Lindblad RW; Dawson P; Wood RA; Henning A; Sicherer SH; Perry TT; Jones SM; Vickery BP; Burks AW; Liu AH
• Predictors of Elevated Rates of Adverse Events While on Peanut Oral Immunotherapy
  Volume: 135 Page(s): AB156 - AB156
  02/01/2015 Authors: Virkud Y; Vickery BP; Steele PH; Kulis MD; Burks AW
• Glutathione S-Transferase Mu 1 (GSTM1) Gene Associated with Allergic Rhinitis in a Food Allergy Cohort
  Volume: 135 Page(s): AB10 - AB10
  02/01/2015 Authors: Chervinskiy SK; Smeester L; Kulis MD; Peden DB; Vickery BP; Fry RC
• Evaluation of Plasma Chemokines and Cytokines in the Setting of Egg Oral Immunotherapy (OIT)
  Volume: 135 Page(s): AB26 - AB26
  02/01/2015 Authors: Albin S; Fei K; Wood RA; Fleischer DM; Sicherer SH; Lindblad RW; Vickery BP; Liu AH; Scurlock AM; Burks AW
• Allergist-reported trends in the practice of food allergen oral immunotherapy.
  J Allergy Clin Immunol Pract Volume: 3 Page(s): 33 - 38
  01/01/2015 Authors: Greenhawt MJ; Vickery BP
• Does clinical protection persist after food allergen oral immunotherapy?
  Immunotherapy Volume: 7 Page(s): 851 - 853
  01/01/2015 Authors: Vickery BP
• Food allergies affect growth in children.
  J Allergy Clin Immunol Pract Volume: 3 Page(s): 133 - 4.e1
  01/01/2015 Authors: Hobbs CB; Skinner AC; Burks AW; Vickery BP
• Food allergy: a practice parameter update-2014.
  J Allergy Clin Immunol Volume: 134 Page(s): 1016 - 25.e43
  11/01/2014 Authors: Sampson HA; Aceves S; Bock SA; James J; Jones S; Lang D; Nadeau K; Nowak-Wegrzyn A; Oppenheimer J; Perry TT
• Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease.
  Nat Genet Volume: 46 Page(s): 895 - 900
  08/01/2014 Authors: Kottyan LC; Davis BP; Sherrill JD; Liu K; Rochman M; Kaufman K; Weirauch MT; Vaughn S; Lazaro S; Rupert AM
• Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
  J Allergy Clin Immunol Volume: 133 Page(s): 468 - 475
  02/01/2014 Authors: Vickery BP; Scurlock AM; Kulis M; Steele PH; Kamilaris J; Berglund JP; Burk C; Hiegel A; Carlisle S; Christie L
• The natural history of egg allergy in an observational cohort.
  J Allergy Clin Immunol Volume: 133 Page(s): 492 - 499
  02/01/2014 Authors: Sicherer SH; Wood RA; Vickery BP; Jones SM; Liu AH; Fleischer DM; Dawson P; Mayer L; Burks AW; Grishin A
• Omalizumab Pretreatment Does Not Protect Against Peanut Oral Immunotherapy-Related Adverse Gastrointestinal Events
  Volume: 133 Page(s): AB104 - AB104
  02/01/2014 Authors: Le U; Virkud Y; Vickery BP; Steele PH; Kamilaris JS; Kulis MD; Berglund J; Burks AW
• Quality Of Life With Sublingual Immunotherapy For Peanut Nicole Leung
  Volume: 133 Page(s): AB103 - AB103
  02/01/2014 Authors: Leung N; Virkud Y; Steele PH; Kamilaris JS; Kim E; Vickery BP; Galvin AD; Burks AW
• Safety Of Pediatric Peanut Oral Immunotherapy Is Complicated By High Adverse Event Rates
  Volume: 133 Page(s): AB154 - AB154
  02/01/2014 Authors: Virkud Y; Vickery BP; Steele PH; Kamilaris JS; Burks AW
• Increases In Peanut-Specific IgA1 and IgA2 During Peanut Immunotherapy Do Not Correlate With Clinical Tolerance
  Volume: 133 Page(s): AB104 - AB104
  02/01/2014 Authors: Yancey AL; Kulis MD; Steele PH; Kim E; Vickery BP; Burks AW
• Length Of Avoidance Period Following Peanut Oral Immunotherapy Influences Effector Cell Suppression and Clinical Outcomes
  Volume: 133 Page(s): AB153 - AB153
  02/01/2014 Authors: Kulis MD; Guo R; Vickery BP; Steele PH; Kim E; Burks AW
• Long-Lasting Egg Consumption in Egg Allergic Children Treated with Oral Immunotherapy (OIT): Follow-up from the Consortium of Food Allergy Research (CoFAR) Study
  Volume: 133 Page(s): AB403 - AB403
  02/01/2014 Authors: Jones SM; Burks AW; Wood RA; Fleischer DM; Sicherer SH; Henning A; Lindblad R; Dawson P; Vickery BP; Keet C
• Peanut OIT-Induced IgG Suppresses Ex Vivo Activation Of Allergic Donor Basophils Via a Combination Of Antigen Interception and Receptor-Bound Inhibition
  Volume: 133 Page(s): AB104 - AB104
  02/01/2014 Authors: Burk C; Kulis MD; Kim E; Vickery BP; Burks AW
• Availability and Utilization Of Epinephrine In Utah Schools For The Management Of Anaphylaxis
  Volume: 133 Page(s): AB25 - AB25
  02/01/2014 Authors: Wright BL; Fogg M; Sparks C; Vickery BP; Roberts JL; Virkud Y; Allison M
• Oral and sublingual immunotherapy for food allergy: current progress and future directions.
  Curr Opin Immunol Volume: 25 Page(s): 781 - 787
  12/01/2013 Authors: Moran TP; Vickery BP; Burks AW
• Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison.
  J Allergy Clin Immunol Volume: 132 Page(s): 476 - 8.e2
  08/01/2013 Authors: Chin SJ; Vickery BP; Kulis MD; Kim EH; Varshney P; Steele P; Kamilaris J; Hiegel AM; Carlisle SK; Smith PB
• The natural history of milk allergy in an observational cohort.
  J Allergy Clin Immunol Volume: 131 Page(s): 805 - 812
  03/01/2013 Authors: Wood RA; Sicherer SH; Vickery BP; Jones SM; Liu AH; Fleischer DM; Henning AK; Mayer L; Burks AW; Grishin A
• Tolerance Induction in an Interim Analysis of Peanut Sublingual Immunotherapy
  Volume: 131 Page(s): AB130 - AB130
  02/01/2013 Authors: Kim E; Chin S; Steele PH; Kamilaris JS; Kamilaris N; Burk C; Vickery BP; Kulis MD; Burks AW
• Impact of Food Allergy On Growth in the Pediatric Population
  Volume: 131 Page(s): AB99 - AB99
  02/01/2013 Authors: Hobbs CB; Skinner AC; Burks AW; Vickery BP
• Life with Peanut: Follow up of Tolerant Versus Desensitized Subjects After Peanut OIT
  Volume: 131 Page(s): AB91 - AB91
  02/01/2013 Authors: Sheikh SZ; Vickery BP; Steele PH; Kamilaris JS; Kulis MD; Carlisle SK; Christie GL; Jones SM; Burks AW
• Development of Tolerance Following Peanut Immunotherapy Is Associated with Basophil Hyporesponsiveness and Low Peanut-IgE:IgG4 Ratio
  Volume: 131 Page(s): AB131 - AB131
  02/01/2013 Authors: Kulis MD; Guo R; Kim E; Vickery BP; Burks AW
• Low-Dose Oral Immunotherapy As an Early Intervention Strategy for Peanut Allergy
  Volume: 131 Page(s): AB130 - AB130
  02/01/2013 Authors: Vickery BP; Steele PH; Kamilaris JS; Burk C; Kamilaris N; Kulis MD; Burks AW
• Changes in IgE and IgG4 Indicative of Desensitization Are Associated with Ara h 1 and 2, but Not Ara h 3, 8, and 9, in Subjects On Sublingual Immunotherapy for Peanut Allergy
  Volume: 131 Page(s): AB330 - AB330
  02/01/2013 Authors: Burk C; Kulis MD; Kim E; Burks AW; Vickery BP
• Predictors of Clinical Tolerance After Peanut Oral Immunotherapy
  Volume: 131 Page(s): AB91 - AB91
  02/01/2013 Authors: Virkud Y; Chin S; Kamilaris N; Kulis MD; Kamilaris JS; Steele PH; Smith PB; Vickery BP; Burks AW
• Clinical Factors and Laboratory Correlates of Egg Allergy Resolution in a Cohort of Infants with Egg Allergy (COFAR)
  Volume: 131 Page(s): AB143 - AB143
  02/01/2013 Authors: Sicherer SH; Wood RA; Vickery BP; Fleischer DM; Jones SM; Henning A; Burks AW; Liu AH; Grishin AV; Mayer LF
• Outcomes and Safety of Oral Food Challenges in a University-Based Clinic
  Volume: 131 Page(s): AB82 - AB82
  02/01/2013 Authors: Moran TP; LaBelle GS; Sedlak DA; Smith PB; Vickery BP; Roberts JL
• Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial.
  J Allergy Clin Immunol Volume: 131 Page(s): 119-27.e1-7
  01/01/2013 Authors: Fleischer DM; Burks AW; Vickery BP; Scurlock AM; Wood RA; Jones SM; Sicherer SH; Liu AH; Stablein D; Henning AK
• Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens.
  J Allergy Clin Immunol Volume: 131 Page(s): 128-34.e1-3
  01/01/2013 Authors: Vickery BP; Lin J; Kulis M; Fu Z; Steele PH; Jones SM; Scurlock AM; Gimenez G; Bardina L; Sampson HA
• Pathogenesis of food allergy in the pediatric patient.
  Curr Allergy Asthma Rep Volume: 12 Page(s): 621 - 629
  12/01/2012 Authors: Chin S; Vickery BP
• Tree nut- and sesame-specific IgE do not decrease from baseline with peanut oral immunotherapy (OIT).
  Ann Allergy Asthma Immunol Volume: 109 Page(s): 470 - 471
  12/01/2012 Authors: Bird JA; Kulis M; Burk CM; Vickery BP; Jones SM; Burks W
• Advances in immunotherapy for food allergy.
  Discov Med Volume: 14 Page(s): 159 - 165
  09/01/2012 Authors: Virkud YV; Vickery BP
• Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children.
  Clin Exp Allergy Volume: 42 Page(s): 1197 - 1205
  08/01/2012 Authors: Thyagarajan A; Jones SM; Calatroni A; Pons L; Kulis M; Woo CS; Kamalakannan M; Vickery BP; Scurlock AM; Wesley Burks A
• Oral immunotherapy for treatment of egg allergy in children.
  N Engl J Med Volume: 367 Page(s): 233 - 243
  07/19/2012 Authors: Burks AW; Jones SM; Wood RA; Fleischer DM; Sicherer SH; Lindblad RW; Stablein D; Henning AK; Vickery BP; Liu AH
• Egg oral immunotherapy.
  Curr Opin Allergy Clin Immunol Volume: 12 Page(s): 278 - 282
  06/01/2012 Authors: Vickery BP
• Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy.
  J Allergy Clin Immunol Volume: 129 Page(s): 1159 - 1162
  04/01/2012 Authors: Kulis M; Saba K; Kim EH; Bird JA; Kamilaris N; Vickery BP; Staats H; Burks AW
• Participation in Peanut Oral Immunotherapy Improves Quality of Life
  Volume: 129 Page(s): AB29 - AB29
  02/01/2012 Authors: Kamilaris JS; Steele PH; Kulis MD; Edie AH; Vickery BP; Burks AW
• Peanut Challenge Outcomes Following Sublingual Immunotherapy (SLIT) Correlate With Increased Peanut-Specific Salivary IgA
  Volume: 129 Page(s): AB65 - AB65
  02/01/2012 Authors: Kulis MD; Saba K; Kim EH; Bird JA; Kamilaris N; Vickery BP; Staats H; Burks AW
• Peanut Oral Immunotherapy and Omalizumab Treatment for Peanut Allergy
  Volume: 129 Page(s): AB28 - AB28
  02/01/2012 Authors: Henson M; Edie A; Steele P; Kamilaris J; Kulis M; Thyagarajan A; Vickery BP; Burks AW
• Induction of Regulatory T Cells After Peanut Sublingual Immunotherapy
  Volume: 129 Page(s): AB27 - AB27
  02/01/2012 Authors: Kim E; Kulis M; Vickery B; Burks A
• A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Egg Oral Immunotherapy in Children: An Analysis of Clinical Tolerance
  Volume: 129 Page(s): AB65 - AB65
  02/01/2012 Authors: Jones SM; Burks AW; Wood RA; Fleischer DM; Sicherer SH; Lindblad RW; Stablein D; Henning AK; Vickery BP; Liu AH
• Early Intervention with Oral Immunotherapy is a Promising Strategy for the Treatment of Peanut Allergy
  Volume: 129 Page(s): AB27 - AB27
  02/01/2012 Authors: Vickery BP; Steele P; Kamilaris J; Edie A; Kulis M; Burks A
• Development of Clinical Tolerance after Peanut OIT
  Volume: 129 Page(s): AB66 - AB66
  02/01/2012 Authors: Burks AW; Vickery BP; Scurlock AM; Steele P; Kamilaris J; Hiegel AM; Carlisle SK; Perry TT; Jones SM
• Comparison of Sublingual Immunotherapy (SLIT) versus Oral Immunotherapy (OIT) in the Treatment of Peanut Allergy
  Volume: 129 Page(s): AB140 - AB140
  02/01/2012 Authors: Chin SJ; Kim EH; Kulis MD; Varshney P; Steele P; Kamilaris J; Hiegel A; Carlisle SK; Scurlock AM; Smith PB
• The antibody response to peanut oral immunotherapy (OIT) is dynamic and individualized
  Volume: 41 Page(s): 1851 - 1852
  12/01/2011 Authors: Vickery B; Lin J; Kulis M; Steele P; Jones SM; Scurlock AM; Bardina L; Sampson HA; Burks AW
• Evidence of desensitization in a study of sublingual immunotherapy for peanut allergy
  Volume: 41 Page(s): 1823 - 1824
  12/01/2011 Authors: Kim E; Bird JA; Kulis M; Laubach S; Shreffler W; Steele P; Kamilaris J; Vickery BP; Burks AW
• Anaphylaxis from peanuts ingested by blood donors?
  N Engl J Med Volume: 365 Page(s): 867 - 868
  09/01/2011 Authors: Vickery BP; Burks AW; Sampson HA
• Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response.
  Immunol Res Volume: 49 Page(s): 216 - 226
  04/01/2011 Authors: Kulis M; Vickery BP; Burks AW
• Pathophysiology of food allergy.
  Pediatr Clin North Am Volume: 58 Page(s): 363 - x
  04/01/2011 Authors: Vickery BP; Chin S; Burks AW
• Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization.
  J Allergy Clin Immunol Volume: 127 Page(s): 640 - 6.e1
  03/01/2011 Authors: Kim EH; Bird JA; Kulis M; Laubach S; Pons L; Shreffler W; Steele P; Kamilaris J; Vickery B; Burks AW
• A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response.
  J Allergy Clin Immunol Volume: 127 Page(s): 654 - 660
  03/01/2011 Authors: Varshney P; Jones SM; Scurlock AM; Perry TT; Kemper A; Steele P; Hiegel A; Kamilaris J; Carlisle S; Yue X
• Mechanisms of immune tolerance relevant to food allergy.
  J Allergy Clin Immunol Volume: 127 Page(s): 576 - 584
  03/01/2011 Authors: Vickery BP; Scurlock AM; Jones SM; Burks AW
• Effect of Peanut Oral Immunotherapy (OIT) on Other Food Allergen-Specific IgE Levels
  Volume: 127 Page(s): AB25 - AB25
  02/01/2011 Authors: Bird JA; Kulis M; Kamilaris N; Varshney P; Pons L; Vickery B; Burks AW
• Basophil Suppression in Peanut Allergic Patients Undergoing Sublingual Immunotherapy (SLIT)
  Volume: 127 Page(s): AB28 - AB28
  02/01/2011 Authors: Chin SJ; Kim EH; Bird JA; Kulis MD; Laubach SS; Pons L; Shreffler WG; Steele P; Kamilaris JS; Vickery BP
• Peanut Oral Immunotherapy (OIT) Induces a Transient Increase in CD4+CD25+FoxP3+Tregs and a Sustained Decrease of Th2-type Cytokines
  Volume: 127 Page(s): AB28 - AB28
  02/01/2011 Authors: Kulis M; Varshney P; Scurlock A; Vickery B; Perry T; Jones S; Burks AW
• Evidence of Desensitization by Sublingual Immunotherapy in Peanut-Allergic Children
  Volume: 127 Page(s): AB72 - AB72
  02/01/2011 Authors: Kim EH; Bird JA; Kulis M; Laubach SS; Shreffler WG; Pons L; Steele PH; Kamilaris J; Vickery BP; Burks AW
• Safe Administration of Flu Vaccine in Egg Allergic Patients
  Volume: 127 Page(s): AB114 - AB114
  02/01/2011 Authors: Boden SR; LaBelle VS; Sedlak DA; Kim EH; Vickery BP; Burks AW
• Clinical Factors And Laboratory Correlates Of Milk Allergy Resolution In A Cohort Of Infants With Milk Allergy (CoFAR)
  Volume: 127 Page(s): AB71 - AB71
  02/01/2011 Authors: Wood R; Jones S; Vickery B; Liu A; Burks W; Fleischer D; Stablein D; Henning A; Mayer L; Sampson H
• Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance.
  Ann Allergy Asthma Immunol Volume: 105 Page(s): 444 - 450
  12/01/2010 Authors: Vickery BP; Pons L; Kulis M; Steele P; Jones SM; Burks AW
• Oral immunotherapy for food allergy.
  Curr Opin Pediatr Volume: 22 Page(s): 765 - 770
  12/01/2010 Authors: Vickery BP; Burks W
• Peanut oral immunotherapy is not ready for clinical use.
  J Allergy Clin Immunol Volume: 126 Page(s): 31 - 32
  07/01/2010 Authors: Thyagarajan A; Varshney P; Jones SM; Sicherer S; Wood R; Vickery BP; Sampson H; Burks AW
• Pediatric food allergy and mucosal tolerance.
  Mucosal Immunol Volume: 3 Page(s): 345 - 354
  07/01/2010 Authors: Scurlock AM; Vickery BP; Hourihane JO; Burks AW
• Targeting Toll-like receptors on dendritic cells modifies the T(H)2 response to peanut allergens in vitro.
  J Allergy Clin Immunol Volume: 126 Page(s): 92 - 7.e5
  07/01/2010 Authors: Pochard P; Vickery B; Berin MC; Grishin A; Sampson HA; Caplan M; Bottomly K
• Peanut Oral Immunotherapy (OIT) Confers Long-Term Tolerance Mediated by Decreased T-helper Type 2 (TH2) Cytokines and Cytokines Generated by Regulatory T cells (Tregs)
  Volume: 125 Page(s): AB20 - AB20
  02/01/2010 Authors: Breslin M; Pons L; Yue X; Kulis M; Jones SM; Vickery B; Burks AW
• Immunoglobulin Changes using Different Dosing Regimens of Peanut Oral Immunotherapy (OIT) in Peanut Allergic Subjects
  Volume: 125 Page(s): AB21 - AB21
  02/01/2010 Authors: Thyagarajan A; Jones SM; Pons L; Kulis M; Smith PB; Steele PH; Kamilaris J; Scurlock AM; Perry TT; Vickery B
• Double-Blinded Placebo Controlled Sublingual Immunotherapy (SLIT) Trial for Peanut Allergy
  Volume: 125 Page(s): AB20 - AB20
  02/01/2010 Authors: Bird JA; Pons L; Kulis M; Kemper AR; Laubach S; Kim E; Varshney P; Thyagarajan A; Steele P; Kamilaris J
• Peanut Oral Immunotherapy (OIT) Induces Epitope-Specific Isotype Shift From IgE to IgG4
  Volume: 125 Page(s): AB20 - AB20
  02/01/2010 Authors: Vickery BP; Lin J; Kulis M; Steele PH; Jones SM; Bardina L; Sampson HA; Burks AW
• Double-Blind, Placebo-Controlled Trial of Oral Immunotherapy (OIT) in Peanut (PN) Allergic Children: A Follow-up
  Volume: 125 Page(s): AB58 - AB58
  02/01/2010 Authors: Jones SM; Scurlock AM; Pons L; Perry TT; Morgan AR; Kulis M; Vickery B; Steele P; Kamilaris J; Hiegel AM
• Adverse reactions during peanut oral immunotherapy home dosing.
  J Allergy Clin Immunol Volume: 124 Page(s): 1351 - 1352
  12/01/2009 Authors: Varshney P; Steele PH; Vickery BP; Bird JA; Thyagarajan A; Scurlock AM; Perry TT; Jones SM; Burks AW
• Immunotherapy in the treatment of food allergy: focus on oral tolerance.
  Curr Opin Allergy Clin Immunol Volume: 9 Page(s): 364 - 370
  08/01/2009 Authors: Vickery BP; Burks AW
• Clinical efficacy and immune regulation with peanut oral immunotherapy.
  J Allergy Clin Immunol Volume: 124 Page(s): 292 - 300.97
  08/01/2009 Authors: Jones SM; Pons L; Roberts JL; Scurlock AM; Perry TT; Kulis M; Shreffler WG; Steele P; Henry KA; Adair M
• Peanut Induced Dendritic Cell (DC) Maturation and Cytokine Production Is Modulated by the Microbial Components of EMP-123, Leading to Changes in Adaptive Immunity In Vitro
  Volume: 123 Page(s): S211 - S211
  02/01/2009 Authors: Vickery BP; Pochard P; Caplan MJ; Sampson HA; Berin MC; Bottomly K
• Skin barrier function in atopic dermatitis.
  Curr Opin Pediatr Volume: 19 Page(s): 89 - 93
  02/01/2007 Authors: Vickery BP
• Successful transcatheter closure of an atrial septal defect in a nickel-allergic patient
  Volume: 119 Page(s): S268 - S268
  01/01/2007 Authors: Vickery B; Askenase P; Kantor F; Asnes J
• Using media messaging to promote healthful eating and physical activity among urban youth.
  J Nutr Educ Behav Volume: 37 Page(s): 98 - 99
  01/01/2005 Authors: Carter BJ; Birnbaum AS; Hark L; Vickery B; Potter C; Osborne MP